Velásquez-Ospina J, Pamplona-Tobón JA, Mejía-Zapata N, Patiño-Giraldo S, Gaviria-Aguilar MC

Language: English
References: 11
Page: 130-135
PDF size: 1724.32 Kb.

ABSTRACT

The treatment of acute coronary syndrome includes the use of acetylsalicylic acid and a P2Y12 inhibitor, with clopidogrel being the most commonly used agent in clinical practice. Fortunately, hypersensitivity reactions to clopidogrel are uncommon; however, when they occur, they are typically type I reactions mediated by IgE (e.g., urticaria, angioedema, and cutaneous rash). Type III hypersensitivity reactions, such as small vessel vasculitis, are exceedingly rare and pose a therapeutic challenge, particularly in the setting of acute coronary syndrome (ACS). This case report shows an uncommon presentation that should be considered in patients receiving antiplatelet therapy.

REFERENCES

1. Shetty RK, Madken M, Naha K et al. Leucocytoclasticvasculitis as a late complication of clopidogrel therapy.BMJ Case Rep. 2013; 2013: bcr2012007861. doi:10.1136/bcr-2012-007861.

2. Erpolat S, Nazli Y, Colak N et al. Leucocytoclasticvasculitis associated with clopidogrel. CutanOcul Toxicol. 2012; 31 (2): 171-173. doi:10.3109/15569527.2011.627578.

3. Lehr S, Meiss F, Kiritsi D et al. Small-vessel vasculitisafter ST-segment elevation myocardial infarction:clopidogrel or amiodarone? JACC Case Rep. 2022; 4(15): 967-971. doi: 10.1016/j.jaccas.2022.05.008.

4. Gutiérrez-Fernández D, Fuentes-Vallejo MS, Rueda-Ygueravides MD et al. Immediate hypersensitivityand delayed hypersensitivity to clopidogrel. AllergolImmunopathol (Madr). 2007; 35 (5): 213-215. doi:10.1157/13110317.

5. Jovanovic M, Sabovic M. Refractory drug-inducedsystemic small-vessel vasculitis with two variedextracutaneous manifestations: a case report andreview of the literature. J Med Case Rep. 2023; 17(1): 470. doi: 10.1186/s13256-023-04174-8.

6. Gil-Ramos JM, Coronado-Magalhaes G, Martínez-Sanchez LM. Vasculitis leucocitoclástica, clasificacióny abordaje diagnóstico. Salutem Scientia Spiritus 2024;10 (1): 43-49.

7. Chanussot-Deprez C, Vega-Memije ME, Flores-SuárezL et al. Etiología de las vasculitis cutáneas: utilidad deuna aproximación sistémica. Gac Med Mex. 2018;154 (1): 62-67. doi: 10.24875/GMM.17002773.

8. Gota CE, Calabrese LH. Diagnosis and treatmentof cutaneous leukocytoclastic vasculitis. Int J ClinRheumatol. 2013; 8 (1): 49-60. doi: 10.2217/ijr.12.79.

9. Jovaní-Casano V, Fernández-Carballido C, Ibero-Díaz I. Vasculitis leucocitoclásticas. En: BelmonteMA, Castellano JA, Román JA, Rosas JC, editores.Enfermedades reumáticas: actualización SVR. 2aed. Valencia: Ibáñez & Plaza Asociados; 2013. p.289-299.

10. Kumbhani DJ, Armbruster AL, Cheng RK et al.Direct oral anticoagulants in primary and secondaryprevention of thrombotic events: 2026 ACC scientificstatement: a report of the American College ofCardiology. J Am Coll Cardiol. 2026. doi: 10.1016/j.jacc.2026.05.033.

11. Gibson CM, Mehran R, Bode C et al. Prevention ofbleeding in patients with atrial fibrillation undergoingPCI. N Engl J Med. 2016; 375 (25): 2423-2434. doi:10.1056/NEJMoa1611594.